Introduction
The secretion of trophic hormones by the anterior pituitary is largely controlled by hypothalamic hypophysiotrophic hormones reaching the gland via the specialized hypophysial portal vasculature. For each of the pituitary hormones, there is a postulated releasing and/or inhibiting hormone. At present, the chemical structure of only three of these compounds (TRH, LHRH and somatostatin), all of which are small peptides, has been established.
Catecholamines occupy a unique position among the various agents associated with homeostasis, since they function both as neurotransmitters in the nervous system, and as hormones in the endocrine system. In fact, catecholamines serve as classical examples of compounds involved in neuroendocrine interactions, and their intimate association with endocrine processes, particularly with reproduction, has been known for decades.
Although much evidence suggests that catecholamines participate in the regulation of secretion of all trophic hormones, their best documented function is the inhibition of pituitary prolactin secretion. The purpose of this presentation is to review the data which establish that dopamine of hypothalamic origin inhibits the secretion of prolactin and to address the question whether dopamine itself functions as a physiological prolactin inhibiting factor (PIF).
Hypothalamic inhibition of prolactin secretion
The evidence for hypothalamic inhibition over the secretion of prolactin is well documented. Hypothalamic lesions or disconnection of the pituitary from the brain, either by stalk section (Diefenbach, Carmel, Frantz & Ferin, 1976 ; Kanematsu & Sawyer, 1973) or by transplan¬ tation of the pituitaries to other sites in the body (Everett, 1954) , result in the cessation of secretion of all trophic hormones while that of prolactin increases. Pituitary glands incubated in vitro release copious amounts of prolactin, but only minute amounts of other hormones. The reverse occurs when hypothalamic extracts are added to incubated pituitaries (Talwalker, Ratner & Meites, 1963) , resulting in a dose-related increase in the secretion of LH, FSH, TSH, etc., concomitant with a proportional reduction in the release of prolactin. Similarly, injection of hypothalamic extracts into experimental animals, either systemically (Amenomori & Meites, 1970) or into hypophysial portal vessels (Porter, Mical, Ben-Jonathan & Ondo, 1973) , reduces circulating prolactin levels but increases those of other hormones.
As the neurohumoral hypothesis developed (Green & Harris, 1947; Scharrer & Scharrer, 1954) , it was postulated that the hypothalamus contains a factor, PIF, which inhibits the secretion of prolactin, and several releasing hormones, each of which stimulates the release of the corresponding trophic hormone. In the absence of a specific target gland hormone to feedback on the pituitary, the control mechanism for the secretion of prolactin seemed relatively simple. It was therefore suggested that all factors able to modify the secretion of prolactin do so by way of changing the hypothalamic content and secretion rates of the postulated PIF. However, it is recognized today that such a model was over-simplified and inadequate. For example, very strong evidence indicates that, in addition to PIF activity, the hypothalamus of several species contains a prolactin releasing activity (PRF) (Nicoli, Fiorindo, McKennee & Parsons, 1970; Valverde, Chieffo & Reichlin, 1972) . TRH, originally thought to be specific for the release of TSH, also stimulates the secretion of prolactin (Bowers, Friesen, Hwang, Guyda & Folkers, 1971) . Indolamines stimulate significant release of prolactin (Kamberi, Mical & Porter, 1971; Maclndoe & Turkington, 1973) and oestradiol acts both in vivo (Bridges & Goldman, 1975) and in vitro (Nicoli & Meites, 1962; Vician, Shupnik & Gorski, 1979) to augment prolactin secretion. Several other compounds, such as GABA (Pass & Ondo, 1977) , enkephalins (Lien, Fenichel, Garsky, Sarantakis & Grant, 1976) and vasoactive intestinal peptide (Kato et al, 1978) , have been shown to modify prolactin secretion. Although some of these effects might be due to pharmacological rather than physiological manifestations, the complex nature of the control of prolactin secretion should be borne in mind.
The ability of catecholamines, and in particular dopamine, to inhibit the secretion of prolactin has been known for a decade. Initially, most of the data were derived from pharmaco¬ logical studies in which the effects of adrenergic drugs on the secretion of prolactin were evaluated. Indeed, a wealth of information exists to indicate that drugs which increase brain catecholamine levels, by enhancing their synthesis or by blocking their degradation, significantly depress serum prolactin levels. On the other hand, drugs known to deplete hypothalamic catecholamines or to block their receptors concomitantly cause elevation in serum prolactin levels (for review see Weiner & Ganong, 1978) .
The pharmacological studies were supported by physiological investigations in which the amines themselves or their precursors were introduced directly into the brain or into the systemic circulation. Administration of dopamine into the third ventricle of rats Ojeda, Harms & McCann, 1974) caused marked reduction in plasma prolactin whereas epinephrine and norepinephrine were less effective. Systemic administration of the catechol¬ amine precursor L-dopa into patients suffering from Forbes Albright syndrome (Turkington, 1972) , monkeys after pituitary stalk section (Diefenbach et al, 1976) or rats with complete lesions of the median eminence (Donoso, Bishop & McCann, 1973) Guillemin, 1978; Schally, 1978 (1979) maintain that both PIF and PRF might be peptides after all.
In parallel with the thrust to isolate the releasing/inhibiting hormones and study their physiology, efforts were undertaken to determine their distribution in the brain. Utilizing immunological, immunocytochemical and microdissection techniques, most researchers agree that the highest concentration of hypophysiotrophic hormones is found in the median eminence in the vicinity of the primary capillary bed of the hypophysial portal vessels (for reviews see Brownstein, 1977; Zimmerman, 1977) . However, these hormones are not confined only to the hypothalamus, as was the general concensus several years ago, but display a wide extrahypothalamic distribution (Oliver, Eskay, Ben-Jonathan & Porter, 1974; Hökfelt et al, 1975) .
In view of the above evidence, it is of interest to note that a marked resemblance exists between the distribution of the hypophysiotrophic hormones and that of catecholamines. Utilizing fluorescent histochemical methods, Fuxe (1965) and Björklund, Moore, Nobin & Stenevi (1973) identified the tubero-infundibular dopaminergic pathway, whose cell bodies are located in the arcuate and paraventricular hypothalamic nuclei, and whose axon terminals are adjacent to the primary capillary plexus of the hypophysial portal vessels. These findings were supported by Kavanagh & Weisz (1974) using a fluorometric method and by Kizer, Palkovits, Tappaz, Kebabian & Brownstein (1976) utilizing a combination of microdissection and radioenzymic assay; both groups found the highest concentration of catecholamines in the pituitary stalk-median eminence region.
A comparison between the subcellular compartmentalization of TRH, LHRH, dopamine and norepinephrine has also been made. Fractionation of hypothalamic homogenates on continuous sucrose density gradients resulted in a similar distribution of TRH, LHRH and the catecholamines. On the basis of sedimentation characteristics as well as susceptibility to detergent treatment and hypo-osmotic shock, Barnea, Ben-Jonathan, Colston, Johnston & Porter (1975) and Barnea, Ben-Jonathan & Porter (1976) concluded that catecholamines, TRH and possibly LHRH are contained in nerve endings, the synaptosomes.
Hypophysial portal blood as the neurovascular link
The anterior pituitary of most mammals receives blood through portal vessels only (for reviews, see Porter et al, 1973; Bergland & Page, 1979 Indeed, the demonstration of PIF activity in portal blood as judged by biological criteria, is yet an unresolved question. Kamberi, Mical & Porter (1970) were unable to show a difference in PIF activity between portal and arterial blood from male rats when tested with hemipituitaries incubated in vitro. However, portal plasma collected from rats after intraventricular injection of dopamine exhibited a significant PIF activity. These results could be interpreted in two ways: either that dopamine caused an increased secretion of PIF into portal blood, or that dopamine itself passed from CSF into portal blood and caused the inhibition of prolactin secretion. ruled out the second possibility, based on their findings that infusion of dopamine into single portal vessels in vivo did not result in the inhibition of prolactin secretion. On the other hand, Takahara, Arimura & reported that when dopamine was dissolved in 5% glucose rather than in saline it had PIF activity when infused into a single portal vessel. The reason for this discrepancy may be that the glucose-containing solution prevented the rapid spontaneous oxidation of dopamine which might have occurred in the saline solution.
The opportunity to search for dopamine in hypophysial portal blood presented itself after the development of a sensitive double-isotope radioenzymic assay , which is capable of measuring simultaneously dopamine, norepinephrine and epinephrine in as little as 25-50 ul of plasma. By utilizing this assay, Ben-Jonathan, Oliver, Weiner, Mical & Porter (1977) reported that the concentration of dopamine, but not that of norepinephrine or epinephrine, was significantly higher in hypophysial portal than in arterial blood from the same rats. Moreover, at times of elevated prolactin secretion, such as during pro-oestrus, dopamine level in portal blood was low, whereas it was elevated during oestrus and dioestrus when plasma prolactin levels in the rat are low. Thus, this observation provided critical evidence that dopamine is released by the hypothalamus into the portal vasculature and therefore could act directly at the pituitary level to inhibit prolactin release. Similar results were later reported by other investigators using either a radioenzymic assay (Cramer, Parker & Porter, 1979) or a liquid chromatographic-electrochemical assay (Gibbs & Neill, 1978) (Bridges & Goldman, 1975) , occurs as a result of direct stimulation of pituitary lactotrophs by oestradiol (Vician et al, 1979) rather than by its action via the dopaminergic system. Smith, 1971) . Vasopressin as well as catecholamines are apparently bound within the granules to proteins, and upon stimulation, both the active compounds and the binding proteins are released into the circulation (Kirshner & Kirshner, 1971 (Saavedra, Palkovits, Kizer, Brownstein & Zivin, 1975; BenJonathan et al, 1980) reported that the concentration of dopamine in the posterior lobe is the same as or exceeds, that of the hypothalamus. Moreover, Axelrod, Albers & Clemente (1959) reported that of all the central nervous system regions, the anterior and posterior lobes of the pituitary contained the highest activity of the enzyme associated with inactivation of cate¬ cholamines, catechol-O-methyl transferase (COMT).
It can be visualized that if dopamine from the posterior lobe is involved in regulating pituitary prolactin secretion, it might reach the anterior lobe via the rich network of capillaries connecting the two lobes (Bergland & Page, 1979 (Smalstig, Sawyer & Clemens, 1974) , ergo¬ cryptine (Pasteeis, Darguy, Frerotte & Ectors, 1971; Caron et al, 1978) and lergotrile (Clemens, Smalstig & Shaar, 1975) , were also effective in inhibiting prolactin secretion, and their action was blocked by the dopamine antagonists haloperidol and pimozide (MacLeod & Lamberts, 1978) . Norepinephrine was also capable of inhibiting prolactin secretion in vitro but at higher doses than those of dopamine (Birge, Jacobs, Hammer & Daughaday, 1970; Shaar & Clemens, 1974; Caron et al, 1978) .
With the development of the method for dispersing viable pituitary cells (Vale, Grant, Amoss, Blackwell & Guillemin, 1972) (Oliver et al, 1974; ). An interesting finding is the demonstration of PIF activity in hypothalami extracted with HC1, whereas the perchloric acid extracts had a slight stimulation rather than inhibition. This observation suggests the presence of a PRF activity in hypothalamic extracts which is more potent than its PIF activity since the perchloric acid extract contains as much catecholamines as the HC1 extract.
Important support for the direct action of dopamine on the anterior pituitary gland came with the identification of specific dopamine receptors in anterior pituitaries of rats, sheep and cows (Brown, Seeman & Lee, 1976; Creese, Schneider & Snyder, 1977; Cronin, Roberts & Weiner, 1978 (Caron et al, 1978) . In addition, agents involved with the secretion of prolactin, such as TRH, oestrogens and catechol- (Spano, Govani & Trabucchi, 1978 
